November 11th 2014
How CTCs and Circulating Naked Tumor DNA-as Liquid Biopsies-Will Transform Diagnostic and Management of Oncology Patients
October 15th 2014
The changes seen in multiple myeloma are a perfect illustration of a potentially shifting paradigm in cancer care.
September 18th 2014
Numerous epidemiological factors affect the likelihood of developing breast and ovarian cancer, but no other predictor is as powerful as an inherited mutation in BRCA1 or BRCA2, genes involved in both tumor suppression and DNA repair.
August 18th 2014
A disruptive study challenges our current system in classifying cancer. Will a new molecular taxonomy of tumors arise and change our views on patient management?
July 21st 2014
The ASCO annual meeting is always a time of excitement for the nearly 30,000 clinicians and scientists who gather every year to see "what's new."
June 19th 2014
The measurement of response to anticancer therapy has evolved over the years as a result of better therapies and progress in imaging.
May 27th 2014
The National Comprehensive Cancer Network (NCCN) guidelines have been a very valuable resource for practicing oncologists for 15 years.
May 2nd 2014
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses NCCN guidelines for the treatment of lymphomas.
April 21st 2014
Medicine is undergoing a revolution that will transform the practice of healthcare, including oncology.
March 26th 2014
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.
There is no question that the era of precision medicine has arrived, and we need to embrace it and resolve together the challenges that come with it, including at the regulatory level.
February 27th 2014
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.
December 13th 2013
Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.
August 14th 2013
Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the immune system.
June 10th 2013
Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, discusses the approval of the immunomodulatory agent lenalidomide (Revlimid).
May 30th 2012
Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.
May 18th 2012
Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga
May 16th 2012
Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL
November 4th 2011
Dr. Andre Goy from John Theurer Cancer Center Explains the Concept of Personalized Medicine
October 14th 2011
Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology